Batm Advanced Communicat... Share Discussion Threads

[gerihatrick] 05/5/2020 07:27

No wonder Zvi has sounded excited in interviews recently.To have both antigen testing and antibody testing achieved in such a short time with the home test kit to come soon augurs well

[dr biotech] 05/5/2020 07:20

5 May 2020

BATM Advanced Communications Limited
("BATM" or "the Group")

BATM launches Antibody Tests for COVID-19 and Commences Sale to European Countries
Shipping commenced to several customers in Europe and ramp up occurring to fulfil further orders

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that its Adaltis subsidiary has launched ELISA Serological Test Kits that diagnose if a patient has had COVID-19 by detecting antibodies against it present in their blood.

The Adaltis Serological Tests are fully CE certified and the Group has commenced shipping initial orders to several customers in Europe. It is now ramping up production for larger quantities to fulfil further orders received from these customers.

Antibodies are proteins produced by the body in response to harmful substances called antigens (e.g. a virus). ELISA (enzyme-linked immunosorbent assay) serological tests measure the amount of various antibodies present in the blood when the body is responding to a specific infection, like COVID-19. The ELISA serological test detects the body's immune response to the infection caused by the virus rather than detecting the virus itself - to help identify those who have been infected and developed antibodies that may protect them from future infection.

Adaltis' ELISA Serological Tests for COVID-19 are designed to test for IgA and IgM (antibodies produced within approximately 4-5 days of the immune system response) as well as IgG antibodies (which are produced after a few weeks and stay present in the body for at least several months), which the Group believes enables the detection of COVID-19 antibodies at an earlier stage than with many competing tests. In addition, Adaltis' tests can be conducted both on standard ELISA machines that are already in widespread use in laboratories and hospitals, and on Adaltis' Personal LAB and NEXgen machines, which are pre-calibrated for these tests. Details of these instruments can be found on the Adaltis website: www.adaltis.com.

Adaltis' ELISA Serological Tests for COVID-19 are complementary to the Group's two previously-announced COVID-19 diagnostics kits, which are both antigen tests (RT-PCR) designed to detect the presence of the virus rather than the immune response to it. The two kits include Adaltis' diagnostic tests that are being shipped for medical facility use and the kits that the Group is developing in partnership with Novamed for home use.

The ELISA serological tests can provide important statistical information to government and health decision makers regarding the number of people who have been infected with COVID-19 and developed immunity in the population. Thus, they have the potential to play an important role in contributing to the strategy for lifting national lockdowns and enabling society to return to more normal activity.

Dr Zvi Marom, Chief Executive Officer of BATM, said: "Adaltis, which invented the magnetic bead separating method - a cornerstone in many of today's in-vitro diagnosis tests - has a great track record of delivering rapid, precise and reliable results to help healthcare professionals make informed decisions. Since the beginning of the COVID-19 outbreak, we have been consistently launching more and more tools as soon as they were rigorously validated and certified by relevant regulatory authorities. First, we produced antigen tests to detect who has COVID-19 and now today we have officially launched tests that detect who has had the COVID-19 virus.

"The serologic tests are now being provided to our customers at a time when they are most needed - to provide statistical information to decision makers. This, together with our other innovative initiatives, will help health authorities in preparing for a potential second wave of COVID-19 in the winter months.

"We are proud of the way our team has responded to this pandemic, and the commercial response to this ELISA serological test that we have developed is testament to the skill and agility of our team. All of this gives me further confidence that BATM is building a world-class diagnostics offering."

[jack jebb] 05/5/2020 07:09

No one had wind of this yesterday then!

[fse] 04/5/2020 18:44

I have not seen Simon Thompsons recent comments.
He did recommend holding about a year ago through to 65p and provided some updates.

Valuing the company is more difficult than normal as we do not know the fall out to the likes of Telco Systems that will see inevitable delays for a couple of quarters but they will recover as there is too much riding on 5G and related solutions.

The medical division is now a considerably larger force with numerous divisions than it was earlier and has the clout to back it up. They have built up a formidable IP. The only caveat here is that these are all new cutting edge solutions that are starting to be marketed.

In this respect I would say that BATM value should support an share price of >65p quite where it will end up will become more apparent as we go forwards.

[gerihatrick] 04/5/2020 17:58

Appreciate your response. Maybe Simon Thompson had the inside line before his comments today. Either way..it looks promising!

[fse] 04/5/2020 15:32

>gerihatrick...... I dont have the numbers on the Hemo one sales. Reference to it was in the latest year end accounts plus Marom has said in the past and in a recent interview that this platform was successful. Thats why I said I was "parking" a few links so I could refer back to them.
They also from what I understand have had a lot of success with the NIPT test.
Link to Hemo One was from a reseller site which I found interesting.

[2toptrader] 04/5/2020 14:33

65p ?! is he having a laugh ?!Take no notice of mr Tonson , this is worth more than that.

[car1pet] 04/5/2020 14:30

Wow well done ST

[paulisi] 04/5/2020 13:25

I'm guessing this was just released and accounts for the spike at 12 o'clock.This guy is influential....

[wynmck] 04/5/2020 12:52

ST raises his valuation to 65p today in IC

[gerihatrick] 04/5/2020 07:22

What do mean by the term "apparently" and who or what is your source? I would just like some numbers...volume, revenue and profitability!

[fse] 03/5/2020 21:54

Just parking some links here for reference.

Apparently selling well. Adaltis product.



MOLgen Covid19 platform

[icemaninvestor] 01/5/2020 13:12

Has anybody seen Space Bob?

[james dean] 01/5/2020 12:45

Folk need to read through the link FSE has put above - a very detailed look at the company - take your time reading it - lots to come IMHO.
.

[car1pet] 01/5/2020 11:06

heavy fall this morning slight recovery as FTSE recovers a little. It feels like 45p/50p is a level for this stock.

[fse] 30/4/2020 17:39

There is quite a bit of current information incorporated in this report and it really lays out the breadth of the company IP which is significant.

[car1pet] 30/4/2020 09:30

nellyb I have got builder to pay. I have had to sell around 20,000 BATM so still got some left. I'm hoping to complete a house sale in the next 2 weeks which will generate some cash for the the rest of the development. Covid has made it harder to sell houses but hopefully will get one over the line in the next 2 weeks.

[gerihatrick] 30/4/2020 09:20

the key for me is that production/sales of test kit is increasing at home test kit in 3 months. Be patient...I am happy with that although some numbers would have been a bonus on the test kits.

[rawdeal1] 30/4/2020 09:00

I must admit, I was expecting the price to tank - it definitely would have done a little while back. The fact that it has not means there is a lot of good support. Good sign I think.

[nellyb] 30/4/2020 08:52

Car1pet, I thought you had a builder to pay!

I'm happy with that RNS. The company expects the Networking & Cyber division to experience a temporary slowdown - due to covid - however, full steam ahead for the Bio-Medical division.

[car1pet] 30/4/2020 08:49

Is it another false dawn